Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimental Ureaplasma murine lung infection model
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01724-24 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Derek Fleming und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Levofloxacin, Doxycycline, Azithromycin, Ureaplasma Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.
Abstract (Originalsprache)
Although lung transplant recipients who develop Ureaplasma- associated hyperammonemia syndrome are treated with Ureaplasma -targeted antibiotics, optimal therapy is incompletely defined, and typically not based on real-time antimicrobial susceptibility testing results. This study compared levofloxacin, azithromycin, and doxycycline prevention and treatment of Ureaplasma urealyticum (UU) and Ureaplasma parvum (UP) infections in an immunosuppressed murine lung infection model. For prophylaxis, mice received antibiotics before infection with UP-FS (susceptible to all study antibiotics), UP-AzmR (azithromycin-resistant), UP-LevR (levofloxacin-resistant), or UU-DoxR (doxycycline-resistant), with lung bacterial loads (color changing units [CCUs]) measured 18 hours following infection. For UP-FS, doxycycline was most active (Δ4.84 log 10 CCU/g; P = 0.0006), followed by levofloxacin (Δ2.45 log 10 CCU/g; P = 0.018), with azithromycin yielding a nonsignificant CCU reduction. Doxycycline (Δ1.9 log 10 CCU/g; P = 0.0025) and levofloxacin (Δ1.3 log 10 CCU/g; P = 0.004) showed activity against UP-AzmR. Only doxycycline showed activity against UP-LevR (Δ2.28 log 10 CCU/g; P = 0.0002), and only azithromycin showed activity against UU-DoxR (Δ0.67 log 10 CCU/g; P = 0.0175). For treatment, antibiotics were administered 24 hours following infection; doxycycline significantly reduced bacterial loads of all study isolates, except UU-DoxR. In addition, azithromycin was active against UP-LevR (Δ1.21 log 10 CCU/g reduction; P = 0.0003). In summary, except for doxycycline-resistant UU, doxycycline was active in preventing and treating Ureaplasma lung infection in immunosuppressed mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Derek Fleming, Robin Patel
Förderung
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
Zitieren
APA
Fleming, D., Al-Jabri, M. Y., & Patel, R. (2025). Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimental Ureaplasma murine lung infection model. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01724-24
Vancouver
Fleming D, Al-Jabri MY, Patel R. Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimental Ureaplasma murine lung infection model. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01724-24
BibTeX
@article{Fleming2025,
author = {Fleming, Derek and Al-Jabri, Maha Y and Patel, Robin},
title = {Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimental Ureaplasma murine lung infection model},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01724-24}
}
EUVIMED